Overview
Dr. Frederick P. Smith is a medical oncologist specializing in breast cancer at Sibley Memorial Hospital and an instructor at Johns Hopkins School of Medicine and Georgetown University School of Medicine. He has a private practice in Washington, D.C. He is affiliated with Sibley Memorial Hospital and Suburban Hospital. Dr. Smith earned his medical degree from Saint Louis University School of Medicine. He completed a residency in internal medicine at Georgetown University Hospital, followed by a fellowship in oncology. Dr. Smith was named a 2012 Top Doctor in the Washington, D.C., Baltimore and Washington-Baltimore areas by Castle Connolly, as well as a Top MD by Consumers’ Checkbook Magazine. Prior to joining Johns Hopkins, Dr. Smith was the director of extramural oncology research at Georgetown University. In this position, he contributed over 50 articles to peer-reviewed medical journals. Dr. Smith is an integral advocate in the community for promoting access to clinical research. He has also contributed to clinical trials.
Dr. Smith is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Ovarian Carcinosarcoma, and Virilizing Ovarian Tumor.
His clinical research consists of co-authoring 3 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE-MEDICAID PLAN
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- HMO
- POS
- PPO
- OTHER MEDICARE
- OTHER MEDICARE PART D
- EPO
- HMO
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- EPO
- POS
- PPO
- HMO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE-MEDICAID PLAN
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- OTHER MEDICARE
- POS
- PPO
- OTHER MANAGED MEDICAID
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE PART D
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE-MEDICAID PLAN
- INSURANCE PLAN
- MEDICARE MAPD
- OTHER COMMERCIAL
- PPO
- EPO
- HMO
- POS
- PPO
- MEDICARE DISCOUNT CARD
- MEDICARE PDP
- OTHER MEDICARE
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
Suite 1640, Chevy Chase, MD 20815
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
1 Clinical Trials
Johns Hopkins Bayview Medical Center
Christine L Hann, completed her MD and Ph.D. at Jefferson Medical College/Thomas Jefferson University follwed by an internal medicine residency at the University of Chicago Hospitals. Following a fellowship at Johns Hopkins University in Hematology and Oncology, Dr. Hann joined the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center as a member of the Upper Aerodigestive Cancer Program and sees patients with non-small cell and small cell lung cancer. Dr. Hann's research focus is on developing novel therapeutics for lung cancer, particularly small cell lung cancer (SCLC) and neuroendocrine tumors (NETs) such as carcinoid tumors of the lung. As a faculty member she is involved in both clinical and laboratory research. Specific research projects include: 1) Studying mechanisms of resistant to small molecule inhibitors of the antiapoptotic protein, BCL-2 using patient-derived xenograft models. Her preclinical work has led to an NCI-sponsored Phase 1/2 clinical trial combining a BCL-2 inhibitor with a TORC1/2 inhibitors which is currently underway (NCT03366103). 2) Preclinical evaluation of various therapeutics including epigenetic modulators (LSD1 inhibitors) and nanoliposome chemotherapy in SCLC PDXs; 3) Modeling and characterizing chemoradiotherapy resistance in preclinical models of SCLC. She, along with Dr. Luigi Marchionni in Biostatistics and Dr. Phuoc Tran in the Department of Radiation Oncology, were recently awarded a 5-year NCI-sponsored U01 grant to study mechanisms of chemoradiation resistance in SCLC. Dr. Hann is PI of several trials in SCLC and NSCLC and is leading investigator-initiated clinical trials in SCLC and NETs. Dr. Hann is rated as an Elite provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. Her top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Squamous Cell Lung Carcinoma.
Inova Health Care Services
Janakiraman Subramanian is an Oncologist and a Hematologist in Fairfax, Virginia. Dr. Subramanian is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Bone Marrow Aspiration, and Tissue Biopsy. Dr. Subramanian is currently accepting new patients.
St Agnes Healthcare Inc
Suman Rao is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Rao is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. Her top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Squamous Cell Lung Carcinoma, and Small Cell Lung Cancer (SCLC). Dr. Rao is currently accepting new patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- ALK-Positive Non-Small Cell Lung CancerDr. Smith isDistinguished. Learn about ALK-Positive Non-Small Cell Lung Cancer.
- Breast CancerDr. Smith isDistinguished. Learn about Breast Cancer.
- Lung AdenocarcinomaDr. Smith isDistinguished. Learn about Lung Adenocarcinoma.
- Ovarian CarcinosarcomaDr. Smith isDistinguished. Learn about Ovarian Carcinosarcoma.
- Paget Disease of the BreastDr. Smith isDistinguished. Learn about Paget Disease of the Breast.
- Pleuropulmonary BlastomaDr. Smith isDistinguished. Learn about Pleuropulmonary Blastoma.
- Advanced
- AngiosarcomaDr. Smith isAdvanced. Learn about Angiosarcoma.
- EGFR Positive Lung CancerDr. Smith isAdvanced. Learn about EGFR Positive Lung Cancer.
- Familial Pancreatic CancerDr. Smith isAdvanced. Learn about Familial Pancreatic Cancer.
- Gastric LymphomaDr. Smith isAdvanced. Learn about Gastric Lymphoma.
- Inflammatory Breast CancerDr. Smith isAdvanced. Learn about Inflammatory Breast Cancer.
- Large-Cell Lung CarcinomaDr. Smith isAdvanced. Learn about Large-Cell Lung Carcinoma.
- Experienced
- Adult Soft Tissue SarcomaDr. Smith isExperienced. Learn about Adult Soft Tissue Sarcoma.
- AgranulocytosisDr. Smith isExperienced. Learn about Agranulocytosis.
- Ampullary CancerDr. Smith isExperienced. Learn about Ampullary Cancer.
- B-Cell LymphomaDr. Smith isExperienced. Learn about B-Cell Lymphoma.
- Bladder CancerDr. Smith isExperienced. Learn about Bladder Cancer.
- Bone TumorDr. Smith isExperienced. Learn about Bone Tumor.